Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19)

NACompletedINTERVENTIONAL
Enrollment

2,006

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

July 24, 2020

Study Completion Date

July 24, 2020

Conditions
Coronavirus InfectionPrevalence
Interventions
BIOLOGICAL

Anti-SARS-CoV-2 IgT seropositivity

"Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."

Trial Locations (1)

54500

Chru Nancy, Vandœuvre-lès-Nancy

All Listed Sponsors
collaborator

University of Lorraine

OTHER

collaborator

Métropole du Grand Nancy

UNKNOWN

lead

Central Hospital, Nancy, France

OTHER

NCT04448769 - Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) | Biotech Hunter | Biotech Hunter